Brief: Oncopeptides Q3 Operating Profit SEK -37.297 Million
08/11/2023 07:00
Nov 08 (Reuters) - Oncopeptides Q3 adjusted free cash flow SEK -57.793 million. * Q3 adjusted EPS SEK -0.45 * Q3 net income SEK -40.543 million * Q3 sales SEK 2.805 million
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy